Convergent Genomics provides UroAmp, a urine‑based liquid biopsy that extracts cell‑free DNA and applies targeted next‑generation sequencing to detect urothelial cancer‑specific mutations and copy‑number alterations. The assay generates a quantitative minimal residual disease (MRD) report within seven days, delivering prognostic and predictive data that enable earlier therapeutic decisions and reduce dependence on invasive cystoscopy.
Funding
Funding not disclosed
Founders
Product
Problem
Current bladder cancer monitoring relies on invasive cystoscopy and low‑sensitivity cytology, leading to delayed detection of recurrence and limited ability to predict disease progression. Clinicians lack a non‑invasive, molecular‑level assay that can reliably identify minimal residual disease (MRD) before it becomes clinically apparent.
Solution
Convergent Genomics addresses this gap with UroAmp, a urine‑based liquid biopsy that extracts cell‑free DNA and applies next‑generation sequencing to detect urothelial cancer‑specific genomic alterations. The test generates a quantitative MRD report that provides both prognostic and predictive insights, enabling earlier therapeutic decision‑making. By leveraging validated clinical data and large observational cohorts, UroAmp delivers high analytical sensitivity and specificity compared with traditional cytology. The workflow integrates seamlessly into urology practices, requiring only a standard urine collection and returning results through a secure clinician portal. This approach shortens the diagnostic timeline, reduces reliance on invasive procedures, and supports personalized management of bladder cancer patients.
Target Audience
The primary customers are urologists, uro‑oncologists, and pathology laboratories that manage bladder cancer surveillance and treatment planning. The test is also relevant to healthcare systems seeking to reduce invasive procedures and improve early detection pathways.
Features
- Urine‑derived cell‑free DNA extraction optimized for low‑input samples
- Targeted next‑generation sequencing panel covering key urothelial cancer driver mutations and copy‑number alterations
- Proprietary bioinformatics pipeline that quantifies MRD burden and generates a clinically actionable report
- Validated analytical performance with sensitivity exceeding conventional cytology for both high‑grade and low‑grade tumors
- Cloud‑based results delivery with encrypted access for clinicians, compatible with existing EMR workflows
- Comprehensive clinical validation dataset spanning multiple observational cohorts to support predictive modeling
- Turnaround time of ≤ 7 days from sample receipt to report issuance